×

Intra-Cellular Therapies to Present Results From Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients With Dementia at the American Neurological Association 139th Annual Meeting

NEW YORK, Oct. 6, 2014 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the Company will present a poster on ITI-007, the Company's lead drug candidate for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders, at the American Neurological Association 139th Annual Meeting. The meeting will be held October 12-14, 2014, in Baltimore. The poster presentation will feature results from ITI-007-200, the Company's Phase I/II clinical trial in healthy geriatric subjects and patients with dementia, including Alzheimer's disease.

ITI-007-200 Poster Presentation:

Poster #M1302: "ITI-007: A Novel Treatment for Behavioral Disturbances Associated with Dementia and Related Disorders". To be presented on Monday, October 13th from 11:00 A.M. to 7:00 P.M EDT. Location: Marriott Waterfront Hotel, Harborside Ballroom.

About Intra-Cellular Therapies

Intra-Cellular Therapies (the "Company") is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disease and other disorders of the central nervous system ("CNS"). The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of cognitive deficits in schizophrenia and other CNS disorders. The Company is also developing inhibitors against additional targets for CNS indications such as Alzheimer's disease, Parkinson's disease and depression and non-CNS indications such as cardiovascular disease.

CONTACT: Intra-Cellular Therapies, Inc. Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations 212-923-3344 Burns McClellan, Inc. Lisa Burns/Angeli Kolhatkar (Investors) Justin Jackson (Media) jjackson@burnsmc.com 212-213-0006

Source:Intra-Cellular Therapies, Inc.